BD HorizonTM RB780 Biosimilar Anti-Human CD20

Description

Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with either BD OptiBuild RB780 Human IgG1 N297A , kappa Isotype Control Cat. No. 756229; Left Plot or BD Horizon RB780 Biosimilar Anti-Human CD20 Obinutuzumab antibody Cat. No. 570975/571046; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations. Flow cytometric analysis was performed using a BD FACSymphony A5 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with BD Horizon BV421 Mouse Anti-Human CD19 antibody Cat. No. 562440 and with either BD OptiBuild RB780 Human IgG1 N297A , kappa Isotype Control Cat. No. 756229; Left Plot or BD Horizon RB780 Biosimilar Anti-Human CD20 Obinutuzumab antibody Cat. No. 570975/571046; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD FACSymphony A5 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with either BD OptiBuild RB780 Human IgG1 N297A , kappa Isotype Control Cat. No. 756229; Left Plot or BD Horizon RB780 Biosimilar Anti-Human CD20 Obinutuzumab antibody Cat. No. 570975/571046; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations. Flow cytometric analysis was performed using a BD FACSymphony A5 Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with BD Horizon BV421 Mouse Anti-Human CD19 antibody Cat. No. 562440 and with either BD OptiBuild RB780 Human IgG1 N297A , kappa Isotype Control Cat. No. 756229; Left Plot or BD Horizon RB780 Biosimilar Anti-Human CD20 Obinutuzumab antibody Cat. No. 570975/571046; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD FACSymphony A5 Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with either BD OptiBuild RB780 Human IgG1 N297A , kappa Isotype Control Cat. No. 756229; Left Plot or BD Horizon RB780 Biosimilar Anti-Human CD20 Obinutuzumab antibody Cat. No. 570975/571046; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations. Flow cytometric analysis was performed using a BD FACSymphony A5 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with BD Horizon BV421 Mouse Anti-Human CD19 antibody Cat. No. 562440 and with either BD OptiBuild RB780 Human IgG1 N297A , kappa Isotype Control Cat. No. 756229; Left Plot or BD Horizon RB780 Biosimilar Anti-Human CD20 Obinutuzumab antibody Cat. No. 570975/571046; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD FACSymphony A5 Cell Analyzer System and FlowJo Software.